Lysunate forte

Lysunate Forte is a high-potency, fixed-dose Artemisinin-based Combination Therapy (ACT) antimalarial that combines two synergistic active pharmaceutical ingredients: artemether and lumefantrine.

• Artemether: A fast-acting semi-synthetic endoperoxide derivative of artemisinin. Upon interaction with intra-parasitic heme iron, it undergoes endoperoxide cleavage, generating short-lived free radicals that rapidly damage essential parasitic proteins and cell membranes. This produces swift clearance of blood-stage schizonts and fast clinical symptom relief within hours.

• Lumefantrine: A long-acting lipophilic synthetic aryl-amino alcohol derivative. It acts by inhibiting the polymerization process that converts toxic free heme into inert hemozoin inside the parasite’s food vacuole. The resulting accumulation of toxic heme causes parasitic membrane destruction and cell death, clearing residual parasites and preventing disease recrudescence.

The Forte formulation increases the concentration of active ingredients to 80 mg artemether and 480 mg lumefantrine per tablet (four times the standard 20 mg / 120 mg adult tablet strength). This lowers the total pill burden for adults from 24 tablets down to just 6 tablets total over the 3-day treatment course.

Primary Medical Indications

Lysunate Forte is indicated for adult and adolescent populations (weighing 35 kg or more) for the treatment of acute parasitic infections:

• Uncomplicated Plasmodium falciparum Malaria: First-line curative treatment for acute, uncomplicated malaria caused by P. falciparum or mixed species infections containing P. falciparum.

• Multi-Drug Resistant Malaria: Highly effective against P. falciparum strains that show resistance to older antimalarial monotherapies such as chloroquine, sulfadoxine-pyrimethamine (Fansidar), or quinine.

• Treatment of Non-falciparum Blood-Stage Parasites: Effective against erythrocytic schizonts of Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae (radical cure for liver hypnozoites in P. vivax and P. ovale requires adjunct therapy with primaquine or tafenoquine).

Key Product Specifications & Dosing Forms

Critical Safety Guidelines & Precautions

• Must Be Taken with High-Fat Food or Milk: Lumefantrine is highly lipophilic and depends heavily on dietary fat for gastrointestinal absorption. Taking Lysunate Forte on an empty stomach drastically lowers drug exposure, risking therapeutic failure and disease relapse.

• Re-Dosing Protocol for Vomiting: If vomiting occurs within 1 hour of administration, a full replacement dose must be taken immediately. If persistent vomiting prevents oral retention, transition the patient to parenteral therapy (e.g., IV or IM artesunate).

• QTc Prolongation Warning: Lumefantrine has the potential to prolong the QTc interval on an ECG. Avoid concurrent use with other QT-prolonging drugs (e.g., macrolide antibiotics, antiarrhythmics, quinine, halofantrine) or in patients with congenital long QT syndrome.

• Not for Severe/Complicated Malaria: Contraindicated as monotherapy for severe or complicated malaria (e.g., cerebral malaria, severe malarial anemia, pulmonary edema). Severe cases require immediate intravenous antimalarial intervention.

• Prophylaxis Restriction: Lysunate Forte is strictly a therapeutic curative agent and must never be used for malaria prophylaxis.